Wiskostatin (Enzo Life Sciences, Exeter, UK) was dissolved in 30% dimethyl sulfoxide (DMSO, Sigma-Aldrich) in normal cell culture medium to a stock concentration of 300 μM. Control reactions received appropriate DMSO treatments. For immunofluorescence and western blot assays, the following primary antibodies were used: paxillin BD610052 (BD Biosciences, Oxford, UK), FAK BD610058 (BD Biosciences, Oxford, UK), pFAK sc11766 (Santa Cruz Biotechnology Inc., USA), nWASP NBP1-82512 (Novus Biologicals, Abingdon, UK) and GAPDH sc32233 (Santa Cruz Biotechnology Inc., USA). The secondary antibodies, AlexaFluor 594 and AlexaFluor 488 (donkey IgG; Life Technologies, Paisley, UK) were used to conjugate to primary antibodies in immunofluorescence assays. DAPI (Merck Millipore, Watford, UK) was used to visualise nuclei. Anti-goat/−mouse/−rabbit IGG whole molecule peroxidase antibodies (Sigma Aldrich) were used to conjugate to primary antibodies in Western blot assays.
Wiskostatin
Manufactured by Enzo Life Sciences
Sourced in United Kingdom
Wiskostatin is a small molecule inhibitor that targets the WASP (Wiskott-Aldrich Syndrome Protein) family. WASP is involved in the regulation of the actin cytoskeleton, which is crucial for various cellular processes. Wiskostatin functions by inhibiting the activity of WASP, thereby modulating the dynamics of the actin cytoskeleton.
Automatically generated - may contain errors
Lab products found in correlation
Blebbistatin, by Merck Group (2 mentions)
Gapdh sc 32233, by Santa Cruz Biotechnology (1 mentions)
Alexa fluor 488, by Thermo Fisher Scientific (1 mentions)
Alexa fluor 594, by Thermo Fisher Scientific (1 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)
4 6 diamidino 2 phenylindole (dapi), by Merck Group (1 mentions)
Bradykinin, by Enzo Life Sciences (1 mentions)
Latrunculin a, by Merck Group (1 mentions)
Ml141, by Merck Group (1 mentions)
Nsc23766, by Bio-Techne (1 mentions)
Wiskostatin, by Merck Group (1 mentions)
Bradykinin, by Merck Group (1 mentions)
Nocodazole, by Merck Group (1 mentions)
Nsc23766, by Merck Group (1 mentions)
2 protocols using wiskostatin
1
Wiskostatin Inhibition of Actin Dynamics
2
Wound Healing Assay with Cytoskeleton Modulators
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Drugs were added 1 h before wounding the monolayer except for the drugs that destabilize the cytoskeleton, which were added 1 h after wounding to allow protrusion formation and initiation of cell migration. Blebbistatin was used at 2 µM, latrunculin A at 20 µM, nocodazole at 10 µM, ML141 (Cdc42 inhibitor) at 10 µM, NSC23766 (Rac1 inhibitor) at 50 µM, wiskostatin (N-WASp inhibitor) at 2 µM, and PKCζ pseudosubstrate at 10 µM. Bradykinin was added 9 h after wounding and 1 h before FRAP experiments at a final concentration of 10 µM. nocodazole, latrunculin A, and ML141 were purchased from EMD Millipore, Blebbistatin from Sigma-Aldrich, NSC23766 from Tocris Bioscience, and wiskostatin, PKCζ pseudosubstrate, and Bradykinin were from Enzo Life Sciences.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!